An Open-Label, Single-Arm Phase 1 Trial to Evaluate the Safety, Tolerability and Efficacy of Vididencel in Chronic Phase Chronic Myeloid Leukemia Patients With Measurable Residual Disease Unable to Meet Requirements of Treatment Free Remission Under Tyrosine Kinase Inhibitor Treatment

The main purpose of the trial is to evaluate the safety and potential side effects of cell therapy vididencel in Chronic Myeloid Leukemia (CML) participants with measurable residual disease (MRD) unable to stop treatment with tyrosine kinase inhibitor (TKI). Patients may not receive any direct medical benefit from participating. Participants in the study should have been treated with TKI for at least 24 months prior to enrolment. This TKI must be of the same type throughout the 24 months. Participation in the active period of the study will take about 5 months after which patients will be followed with regular checks for a total of 3 years from the study start. The cell therapy is administered as 2 low-volume intradermal injections.The first 4 treatments will be performed once every two weeks over a period of 6 weeks. Further treatments are given 14 and 18 weeks after the start of participation as 1 low-volume intradermal injection.The belief is that addition of the study treatment (vididencel) to tyrosine kinase inhibitor therapy may potentially strengthen the immune defence so that enough leukemic cells are killed that the TKI treatment can eventually be decreased in dose or even stopped permanently, without the CML progressing again.

开始日期2026-04-14

申办/合作机构

Mendus AB

[+1]

NCT04739527

/ Completed临床1期

An Open Label, Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment

Phase I study to evaluate safety and systemic immunogenicity of the DCP-001 vaccine in patients with high grade serous ovarian cancer after primary treatment.

开始日期2021-06-10

申办/合作机构

Universitair Medisch Centrum Groningen

[+1]

NCT03697707

/ Unknown status临床2期

An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD

Phase II study to evaluate safety and efficacy of DCP-001 in patients with AML in CR, and with presence of MRD

开始日期2018-10-15

申办/合作机构

Mendus AB

[+1]

100 项与 Vididencel 相关的临床结果

登录后查看更多信息

100 项与 Vididencel 相关的转化医学

登录后查看更多信息

100 项与 Vididencel 相关的专利（医药）

登录后查看更多信息

项与 Vididencel 相关的文献（医药）

2023-12-01·International journal of biological macromolecules

Isolation and characterization of a nephroprotective polysaccharide from Dendrobium chrysotoxum Lindl against LPS-induced acute kidney injury mice

Article

作者: Liu, Hailin ; Lao, Shenghui ; Hao, Yuting ; Liao, Wenzhen ; Chen, Xiao ; Ye, Guangying ; Wang, Zaihua

The structure and bioactivity of a novel polysaccharide from Dendrobium Chrysotoxum Lindl (DCP-1) were investigated. The crude polysaccharides of Dendrobium Chrysotoxum Lindl (DCP) were extracted by hot water extraction, and the protein was removed by enzymatic hydrolysis and Sevage. After purification, the chemical structure of polysaccharides was identified by infrared spectroscopy, methylation analysis and nuclear magnetic resonance spectroscopy. Then, a mouse model of acute kidney injury (AKI) was constructed using lipopolysaccharide (LPS), and pretreated with DCP. Structure characterization demonstrated that the number-average molecular weight and mass average molar mass of DCP-1 were 28.43 kDa and 15.00 kDa, respectively. DCP-1 mainly consisted of mannose (37.8 %) and glucose (55.6 %). The main linkage types of DCP-1 were contained 1,4-Linked Manp and 1,4-Linked Glcp. And DCP-1 was demonstrated to be an O-acetylglucomannan with β-ᴅ-configuration in pyranoid form. Besides, the bioactivity of DCP was further investigated. The results showed that DCP exhibited notable anti-inflammatory activity in LPS-induced AKI mice. After treated with DCP, the creatinine (CREA) and urea nitrogen (BUN) in serum were successfully down-regulated in AKI mice. DCP treatment prevented the characteristic morphological changes of LPS-induced renal tubular injury. The results showed that DCP treatment significantly reduced the concentration of oxidative damage indicators (MDA, SOD) and the expression of inflammatory indices (TNF-α, IL-6, MCP-1, COX-2). In general, the newly extracted polysaccharide DCP showed excellent nephroprotective effect, which enabled it to be an ideal natural medicine for kidney diseases therapy.

2018-10-01·Cancer immunology, immunotherapy : CII2区 · 医学

A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia

2区 · 医学

Article

作者: Singh, Satwinder Kaur ; de Gruijl, Tanja D ; Kruisbeek, Ada M ; Eeltink, Corien M ; van de Loosdrecht, Arjan A ; den Hartog, Yvonne ; Santegoets, Saskia J A M ; Kaspers, Jorn ; Koppes, Malika ; van Wetering, Sandra ; Ossenkoppele, Gert J

In elderly acute myeloid leukemia (AML) patients post-remission treatment options are associated with high comorbidity rates and poor survival. Dendritic cell (DC)-based immunotherapy is a promising alternative treatment strategy. A novel allogeneic DC vaccine, DCP-001, was developed from an AML-derived cell line that uniquely combines the positive features of allogeneic DC vaccines and expression of multi-leukemia-associated antigens. Here, we present data from a phase I study conducted with DCP-001 in 12 advanced-stage elderly AML patients. Patients enrolled were in complete remission (CR1/CR2) (n = 5) or had smoldering disease (n = 7). All patients were at high risk of relapse and ineligible for post-remission intensification therapies. A standard 3 + 3 dose escalation design with extension to six patients in the highest dose was performed. Patients received four biweekly intradermal DCP-001 injections at different dose levels (10, 25, and 50 million cells DCP-001) and were monitored for clinical and immunological responses. Primary objectives of the study (feasibility and safety) were achieved with 10/12 patients completing the vaccination program. Treatment was well tolerated. A clear-cut distinction between patients with and without detectable circulating leukemic blasts during the vaccination period was noted. Patients with no circulating blasts showed an unusually prolonged survival [median overall survival 36 months (range 7-63) from the start of vaccination] whereas patients with circulating blasts, died within 6 months. Long-term survival was correlated with maintained T cell levels and induction of multi-functional immune responses. It is concluded that DCP-001 in elderly AML patients is safe, feasible and generates both cellular and humoral immune responses.

2017-11-01·Journal of immunotherapy (Hagerstown, Md. : 1997)4区 · 医学

DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma

4区 · 医学

Article

作者: Avigan, David ; Apel, Arik ; Nahas, Myrna R. ; Pyzer, Athalia R. ; Leaf, Rebecca Karp ; Cole, Leandra ; Washington, Abigail ; Arnason, Jon ; Morin, Adam ; van Wetering, Sandra ; Jain, Salvia ; Stroopinsky, Dina ; Ephraim, Adam ; Hamdan, Ayad ; Rosenblatt, Jacalyn ; Kruisbeek, Ada M.

Multiple myeloma (MM) is characterized by progressive immune dysregulation, loss of myeloma-specific immunity, and an immunosuppressive milieu that fosters disease growth and immune escape. Accordingly, cancer vaccines that reverse tumor-associated immune suppression represent a promising therapeutic avenue of investigation. We examined the potential of an allogeneic cellular vaccine to generate immune responses against MM tumor cells. The DCOne vaccine is comprised of a human myeloid leukemia cell line differentiated into a fully functional dendritic cell, expressing a range of tumor-associated antigens that are also known targets in MM. We found that the myeloma-specific antigens expressed by the DCOne vaccine can traffic via extracellular vesicles to surrounding antigen-presenting cells, thus stimulating autologous T-cell responses. Indeed, coculture of peripheral blood mononuclear cells from patients with MM with the DCOne vaccine resulted in the expansion of activated CD8+ T cells expressing interferon-γ and perforin, with no significant change in the percentage of CD4+ T cells producing interleukin-10. Further, coculture of patient’s tumor cells with peripheral blood mononuclear cells and DCOne induced cytotoxic T-lymphocyte-mediated killing of autologous MM cells. These findings demonstrate that the allogeneic DCOne vaccine can induce T-cell activation and myeloma-specific immunity via cross presentation of antigens by native antigen-presenting cells.

项与 Vididencel 相关的新闻（医药）

2026-06-04

·康和源免疫之家

癌症疫苗时代开启！黑色素瘤、食管癌、卵巢癌……癌症疫苗最新突破：3年无复发生存率超70%

癌症疫苗是近年来肿瘤治疗领域极受关注的方向之一。提到疫苗，可能会想起小时候打过的乙肝疫苗、破伤风针。但癌症疫苗完全不是一回事，它不是用来防感冒的，它的使命是在你体内建立起一支专门识别并追杀癌细胞的“特种部队”。什么是癌症疫苗癌症疫苗与流感疫苗不同。流感疫苗是预防性的，对所有人都是一样的。癌症疫苗具有治疗效果，适用于已患癌的患者。癌细胞之所以能逃避免疫系统的追杀，是因为它们善于“伪装”，让免疫细胞（尤其是T细胞）认不出它们是“坏蛋”。治疗性疫苗的作用，就是充当“免疫教官”，把癌细胞特有的“身份证”展示给免疫系统看，教会T细胞精准识别并消灭它们。癌症疫苗可分为个性化定制疫苗和通用现货型疫苗两大类。个性化疫苗针对每位患者的独有突变进行个体化设计，理论上精准度最高，但生产成本较高，制备周期通常需8至12周。通用型疫苗则靶向多种肿瘤共有抗原，可批量生产、即取即用，覆盖面广但免疫反应强度或略逊一筹。两者各有适用人群，并无绝对的优劣之分。如果您或家人正面临黑色素瘤、食管癌、肺癌、肾癌等实体瘤术后辅助治疗或晚期治疗的选择困境，希望深入了解个体化癌症疫苗（包括mRNA疫苗、多肽疫苗等）的最新全球临床试验进展、评估自身肿瘤的基因测序结果是否符合入组条件，请联系康和源免疫之家（400-880-3716）。最近，一系列重磅数据让癌症疫苗不再是纸上谈兵，而是真正拿出了长期生存的硬指标。黑色素瘤辅助治疗，5年复发风险降低49% 在ASCO 2026上，Moderna与默沙东联合公布了其个体化mRNA新抗原疫苗intismeran autogene（mRNA-4157）联合帕博利珠单抗，用于高危可切除黑色素瘤辅助治疗的5年长期随访数据。这项名为KEYNOTE-942的II期研究结果，为癌症疫苗的长期疗效提供了有力的证据。中位随访超过60个月后，与单独使用帕博利珠单抗相比，联合mRNA-4157治疗将患者的复发或死亡风险降低了49%，将远处转移或死亡风险降低了59%。更重要的是，这种获益在几乎所有亚组中均保持一致，包括不同疾病分期、PD-L1表达状态、BRAF突变状态的患者。尤其值得注意的是，在基线循环肿瘤DNA检测为阴性（即分子层面微小残留病灶水平极低）的患者中，联合治疗组的复发风险降低幅度高达76%，这强烈提示疫苗在清除微量残留病灶、预防复发方面具有巨大潜力。卵巢癌新希望，部分患者无进展生存超3.5年在2026年ASCO年会上公布的ALISON试验数据，为卵巢癌治疗带来了一线希望。这项1b期临床试验由Mendus公司与荷兰格罗宁根大学医学中心合作开展，共纳入17名高级别浆液性卵巢癌患者。所有患者在接受标准治疗（手术和化疗）后，接受了6次皮内注射vididencel治疗。在中位随访26.4个月时，数据显示出令人鼓舞的结果。在11名完成预设2年随访的患者中，8人仍然存活，其中5人保持长期无进展生存。特别值得注意的是，有2名患者的无进展生存期已超过3.5年。中国方案崛起，食管癌3年无复发生存率超70% 来自中国浙江大学医学院附属第二医院团队在ASCO上报告了另一项个体化癌症疫苗的杰出成果。针对的是中国高发且预后极差的食管鳞状细胞癌。研究使用的iNeo-Vac-P01是一种个体化新生抗原多肽疫苗。在中位随访近30个月时，其3年无复发生存率超过70%，3年总生存率超过80%。这一数据显著优于国际III期研究CheckMate 577中纳武利尤单抗辅助治疗食管鳞癌患者36%的3年RFS率，也优于其他国内PD-1抑制剂围手术期疗法的数据。尤为重要的是，所有已报道的患者均未出现3级及以上疫苗相关不良反应，安全性卓越。骨肉瘤mRNA疫苗初显成效，安全可控上海市第六人民医院开展的国内首例个体化mRNA新抗原疫苗治疗骨肉瘤的探索性研究也传来积极信号。初步数据显示，受试者体内成功诱导出特异性免疫应答，部分患者肿瘤缩小或保持稳定，且安全性良好。这为缺乏有效治疗手段的晚期骨肉瘤患者带来了新希望。综上可见，癌症疫苗在癌症治疗方案展现出最有前景的临床价值。目前，癌症疫苗正在国内积极开展临床研究，有意向参与临床试验接受前沿治疗的患者，请联系康和源免疫之家（400-880-3716）。结语癌症疫苗的时代大门已经开启。它或许还不能治愈所有癌症，但它正以前所未有的精准度，教会我们自身的免疫系统如何更聪明、更持久地对抗癌症。癌症疫苗可能并不适合所有人，但我们希望你知道：在你以为“只能等着复查、等着复发”的时候，其实还有新的选项正在临床试验中、正在国内落地、正在改变一些人的结局。参考资料 1.https://irp.cdn-website.com/89dd0539/files/uploaded/Moderna_ASCO+FINAL+.pdf 2.https://mendus.com/news/mendus-reports-long-term-progression-free-survival-associated-with-broad-immune-activation-in-high-risk-ovarian-cancer/ 3.https://www.mdpi.com/2076-393X/13/12/1231 4.https://www.aicr.org/resources/blog/cancer-vaccines-a-new-frontier-in-cancer-prevention-and-treatment/ 5.https://www.aacr.org/blog/2026/02/20/aacr-io-2026-keynote-highlights-cancer-vaccines-are-here-and-upgrading-t-cells-to-thrive-in-the-tumor-microenvironment/ 6.https://news.mit.edu/2026/new-approach-cancer-vaccination-yields-more-powerful-t-cells-0513 7.https://news.mit.edu/2026/new-approach-cancer-vaccination-yields-more-powerful-t-cells-0513 如果您在阅读本文后仍有困惑，或需要帮助，可通过康和源免疫之家医学部（400-880-3716）获取专业指导。您可以通过添加以下微信方式联系我们。赵老师微信：15810815293 曹老师微信：17801183037 康和源免疫之家-癌症患者的生命希望桥梁康和源免疫之家作为肿瘤诊疗服务平台，始终秉持“以患者为中心”的理念。在肿瘤治疗领域，患者面临着巨大的身心压力和复杂的治疗选择，康和源免疫之家深知患者的需求和困境，致力于为患者提供全方位、个性化的服务。为了实现这一目标，该平台整合了中国、美国、欧洲、日本、韩国等全球顶尖肿瘤专家资源。这些专家拥有丰富的临床经验和先进的治疗理念，能够为患者提供专业的诊断和治疗建议。同时，平台还与知名药企、创新药物研发机构建立了深度合作关系，这使得患者能够及时了解到前沿的抗癌药物和治疗技术，为治疗提供更多的选择。国际专家会诊服务肿瘤治疗具有复杂性和个体差异性，不同患者的病情和身体状况各不相同，因此需要个性化的治疗方案。康和源免疫之家通过国际专家会诊服务，可协调中美欧日韩等多国权威肿瘤专家，针对癌症开展跨国联合诊疗。对于那些需要第二诊疗意见的患者来说，国际专家会诊可以提供不同的视角和建议，帮助患者更全面地了解自己的病情和治疗方案。而对于寻求海外先进治疗方案的患者，平台的专业团队能够帮助他们获取国际前沿治疗指南，为患者制定更加科学、合理的治疗计划。临床试验作为连接患者与创新疗法的纽带，康和源免疫之家与全球领先药企及研发机构保持战略合作，持续提供涉及PD-1/L1抑制剂、CAR-T细胞治疗、ADC药物等领域的临床试验项目。这些临床试验项目代表了当前癌症治疗的前沿进展和研究方向，为患者提供了接触新型抗癌药物和治疗技术的机会。康和源免疫之家团队会根据患者的病情阶段、基因检测结果和治疗史，精准匹配适合的临床试验机会。这不仅提高了患者参与临床试验的成功率，也确保了患者能够接受更加适合自己的治疗。在康和源免疫之家，每个生命都被视为值得更好的医疗选择，无论是寻求国际顶尖专家的诊疗建议，还是尝试突破性的临床试验，平台都将竭诚为患者提供专业、可靠的全方位支持。让我们携手，在抗击肿瘤的征程上走得更远。 END 如果您或您身边的人正在遭受癌症的困扰，不妨拨打咨询电话400-880-3716，登录官网 https://www.myimm.net/或关注微信公众号“康和源免疫之家”（头条、知乎、百度、搜狐等自媒体同名），了解更多关于临床试验和肿瘤诊疗服务的信息。 🌿抗癌，不仅是力量的抗争，更是精准的博弈。🌿 当亲人面对癌症，我们常问：“什么治疗方案更有效？会不会产生耐药？这种病会遗传给家人吗？”这些关乎生存与未来的关键问题，答案可能就藏在每个人的基因里。 🧬基因检测：为患者点亮精准治疗的“导航”，为家属揭开遗传风险的“谜底”。🧬 精准打击肿瘤，避免无效治疗肿瘤千差万别，用药也需“量体裁衣”。我们的基因检测能明确揭示肿瘤的基因突变靶点，就像为导弹装上“精确制导系统”，快速匹配更可能有效的靶向药物，避免在无效的化疗中消耗宝贵的生命与希望。评估遗传风险，为家人构筑健康防线部分癌症与遗传密切相关。通过基因检测，可以评估患者是否携带明确的遗传易感基因突变。这不仅解释了病因，更能为您的子女、兄弟姐妹等近亲提供至关重要的预警，让他们能及早干预，主动守护健康。 🔬康和源免疫之家，用基因图谱，守护您与家人的生命延续。🔬 我们提供的不仅是冰冷的报告，更是一份贯穿诊断、治疗与康复的“科学行动指南”。我们的医学专家将为您深度解读基因信息，在复杂的治疗选择中提供决策支持，并为整个家庭的健康风险管理提供专业建议。 📞一人检测，可能惠及全家。立即拨打400-880-3716，康和源免疫之家医学部，为您与家人的未来，提供一份科学的答案。让科学指引方向，让选择更有力量。扫描下方二维码，或者直接电话咨询康和源免疫之家医学部（400-880-3716），持续为您关注并分享癌症前沿消息。免责声明:文本参考来源于网络，版权归原作者所有。该文章仅供分享，如涉嫌侵犯您的著作权请联系我们删除，谢谢！

2026-05-16

·mendus.com

Mendus reports long-term progression-free survival associated with broad immune activation in high-risk ovarian cancer

• ALISON trial data presented at ASCO demonstrate broad immune activation and support further evaluation of vididencel in combination approaches to improve durable disease control • Five participants of the trial remained progression-free at long-term follow-up, including two beyond 3.5 years • Vididencel-induced immune responses correlate with long-term progression-free survival and involve multiple immune compartments Mendus AB (publ; IMMU.ST) reported additional positive results from the Phase 1b ALISON trial in high-grade serous ovarian cancer (HGSOC) at the world’s largest cancer conference, ASCO 2026, in Chicago, USA. The data show that vididencel induces broad anti-tumor immune responses associated with improved progression-free survival, supporting its potential as a combination immunotherapy for this difficult-to-treat cancer. Ovarian cancer is the deadliest gynecological cancer largely due to its high rates of recurrence and the emergence of treatment-resistant disease following initial therapy. The ALISON Phase 1b trial evaluates vididencel as an active immunotherapy in late-stage HGSOC, with the aim to improve the durability of clinical responses and prolong progression-free survival (PFS). The study enrolled 17 women diagnosed with HGSOC, who were treated with six intradermal vididencel injections following standard chemotherapy and surgery. At a median follow-up of 26.4 months, 11 patients had reached the predefined 2-year survival follow-up, 8 patients were alive of whom 5 were still in long-term PFS, including 2 beyond 3.5 years of follow-up. The ALISON trial is part of an ongoing collaboration between Mendus and the University Medical Center Groningen, The Netherlands (UMCG) to study novel immunotherapies for gynecological cancers. Mendus and UMCG had previously reported stimulation of tumor-directed T cell responses following vididencel treatment, which were associated with improved PFS in HGSOC. The immune profiling data presented at ASCO reveal that vididencel-induced immune responses involve multiple compartments of the immune system, including dendritic cells, B cells and memory NK cells. “After initially showing that vididencel has the potential to stimulate tumor-directed T cells, we have now taken the next steps in deciphering the immune signatures of the samples collected during the ALISON trial,” said Professor Marco de Bruyn, Head of the Immuno-oncology research group at UMCG. “B cells have been suggested to play an important role in the control of gynecological cancers and there is a growing interest in the role of other cell types such as memory NK cells. It is therefore encouraging that we observe an increase of these cell populations following vididencel treatment, which may contribute to long-term disease control.” “Recurring tumors in ovarian cancer are among the hardest-to-treat cancers and new therapeutic options to prolong clinical responses and extend survival without harming health or quality of life will therefore have a major impact on prospects for women diagnosed with this fatal disease,” said Mendus Chief Medical and Scientific Officer Tariq Mughal. “The ALISON trial data presented at ASCO reveal the breadth of the immune responses following vididencel treatment, combined with an excellent safety and tolerability profile. This provides a basis to study vididencel in combination with other approved and upcoming treatment modalities, including PARP inhibitors, antibody-drug conjugates (ADCs) and bispecific antibodies.” The findings of the ALISON trial confirm the proposed mechanism of action for vididencel as an active immunotherapy that stimulates immune control over residual cancer cells and extend previous observations in other tumor settings characterized by residual disease following initial treatment. The company’s clinical development strategy remains focused on myeloid blood cancers, while further clinical development of vididencel in combination with other therapeutic modalities in HGSOC will be subject to partnering.

2026-05-08

·mendus.com

Mendus AB Interim Report January – March 2026

Start of clinical program in chronic myeloid leukemia As part of its updated clinical strategy communicated end of 2025, Mendus is expanding clinical development of the lead product vididencel to include chronic myeloid leukemia (CML). Enrollment of the first patient in the VITAL-CML trial marked the start of clinical development in CML. In parallel, Mendus started a collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI), a leading Australian cancer research institute, to support the DIVA trial in acute myeloid leukemia (AML). The trial will commence in the summer and assess vididencel in combination with less intensive induction therapy, further consolidating the position of vididencel as a post-remission immunotherapy.Erik Manting, Ph.D.Chief Executive Officer Significant events of Q1 2026 Net sales for the period amounted to KSEK – (-) Result for the period amounted to KSEK –21,022 (-30,482) Earnings and diluted earnings per share totaled to SEK –0.34 (-0.61) Mendus entered into an agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI), a leading Australian cancer research institute, to support the DIVA trial with the company’s lead product vididencel in AML (acute myeloid leukemia). Mendus requested drawdown of SEK 30 million under the loan facility totaling SEK 50 million entered into with Fenja Capital II A/S in November 2025. Furthermore, the company's board of directors resolved, pursuant to the authorization from an extraordinary general meeting in December 2025, and in accordance with the terms and conditions of the loan facility, on a directed issue of 1,935,605 warrants of series 2025/2030 to Fenja. Significant events after end of reporting period Mendus announced an Mendus announced start of clinical program in CML (chronic myeloid leukemia). The company has completed preparations and received all regulatory approvals for the VITAL-CML trial, marking the start of clinical development with the company’s lead product vididencel CML. Mendus announced that the first patient has been enrolled in the VITAL-CML trial, which evaluates vididencel in chronic phase CML patients with a sub-optimal response to currently approved tyrosine kinase inhibitors (TKIs). Financial summary The full report is attached as PDF and is available on the company’s website: https://mendus.com/investors/financial-reports/ Webcast investor call, May 8 at 14.00 CESTThe company will host a live presentation and business update today at 14:00 CEST. The presentation will be held in English and includes a Q&A session. If you wish to participate via webcast please use the link below. Via the audiocast you are able to ask written questions.https://mendus.events.inderes.com/q1-report-2026/register If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.https://events.inderes.com/mendus/q1-report-2026/dial-in For more information, please contact:Erik MantingChief Executive OfficerE-mail: ir@mendus.com About Mendus AB (publ)Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies that combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/ AttachmentsMendus 26Q1 ENGMendus AB Interim Report January – March 2026

临床研究免疫疗法

100 项与 Vididencel 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性髓性白血病	临床2期	澳大利亚	Mendus AB	2024-06-14
复发性急性髓细胞白血病	临床2期	芬兰	Mendus AB	2018-10-15
复发性急性髓细胞白血病	临床2期	德国	Mendus AB	2018-10-15
复发性急性髓细胞白血病	临床2期	荷兰	Mendus AB	2018-10-15
复发性急性髓细胞白血病	临床2期	挪威	Mendus AB	2018-10-15
复发性急性髓细胞白血病	临床2期	瑞典	Mendus AB	2018-10-15
残留肿瘤	临床2期	芬兰	Mendus AB	2018-10-15
残留肿瘤	临床2期	德国	Mendus AB	2018-10-15
残留肿瘤	临床2期	荷兰	Mendus AB	2018-10-15
残留肿瘤	临床2期	挪威	Mendus AB	2018-10-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04739527 (ASCO2026)	临床1期	卵巢癌	17	Vididencel	遞築鑰憲製壓遞膚製憲(膚淵膚糧淵願製繭餘構) = 範繭鹽觸餘齋鹽醖壓鏇淵築膚淵鑰鬱遞鹽獵鏇 (鹹醖廠積鹹顧鏇憲壓願 ) 更多	积极	2026-05-29
ASH2025	临床2期	急性髓性白血病一线	20	Vididencel	選鬱夢鹹窪製鹽鬱淵構(糧繭廠願壓簾簾築築鑰) = 蓋膚鹽壓鏇窪觸願醖遞憲鏇鬱製積願鑰鬱鏇鹽 (遞積壓衊獵積壓膚夢醖, 42.5 ~ 82.3) 更多	积极	2025-12-06
NCT03697707 (ADVANCE II, Company_Website) 人工标引	临床2期	急性髓性白血病	-	Vididencel	淵遞壓鬱觸廠網願廠窪(簾鹹衊顧築積夢選鏇獵) = 繭遞獵窪製願鹽鹹蓋築醖遞糧廠壓鹹鏇膚糧鏇 (選餘鬱獵餘觸衊積窪鹽 )	积极	2025-05-16
NCT03697707 (ADVANCE-II, EHA2025)	临床2期	急性髓性白血病 NPM1 mutation \| NPM1 wild type	20	VIDIDENCEL (NPM1 mutated AML patients)	壓遞廠範襯積廠鑰願鹽(廠選醖艱網齋鏇觸淵窪) = 憲範襯壓範襯窪選夢艱鑰鏇網獵製願顧積鏇憲 (觸衊選鏇夢獵餘窪範鹽 ) 更多	积极	2025-05-14
NCT03697707 (ADVANCE-II, EHA2025)	临床2期	急性髓性白血病 NPM1 mutation \| NPM1 wild type	20	VIDIDENCEL (NPM1 wild type AML patients)	壓遞廠範襯積廠鑰願鹽(廠選醖艱網齋鏇觸淵窪) = 鹹餘選製衊顧醖憲艱廠鑰鏇網獵製願顧積鏇憲 (觸衊選鏇夢獵餘窪範鹽 ) 更多	积极	2025-05-14
NCT04739527 (ALISON, NEWS) 人工标引	临床1期	卵巢癌	17	Vididencel	觸選簾膚醖夢選鏇糧願(襯獵憲憲淵鬱願壓願顧) = 窪淵簾膚餘糧廠壓膚築繭蓋範壓簾壓選網鏇夢 (憲衊簾鬱壓壓範鹹艱窪 ) 更多	积极	2024-12-18
NCT03697707 (ADVANCE-II, ASH2023) 人工标引	临床2期	急性髓性白血病	20	Vididencel	餘膚選簾鏇範網糧淵築(鏇簾鬱壓艱積齋衊壓糧) = none 網簾觸範鑰繭憲製衊襯 (衊夢製淵齋鑰艱鹹遞顧 ) 更多	积极	2023-12-11
NCT01373515 (Literature) 人工标引	临床1期	急性髓性白血病 \| 高危骨髓增生异常综合征维持	12	DCP-001 (Responder)	鑰製蓋鹹夢壓夢廠壓積(艱蓋鑰範觸鬱築餘淵窪) = 繭蓋窪襯夢鹽膚壓築構顧壓廠餘廠廠淵蓋餘顧 (衊廠餘壓顧蓋膚壓蓋壓, 90–1849) 更多	积极	2023-11-02
NCT01373515 (Literature) 人工标引	临床1期	急性髓性白血病 \| 高危骨髓增生异常综合征维持	12	DCP-001 (Non-responder)	鑰製蓋鹹夢壓夢廠壓積(艱蓋鑰範觸鬱築餘淵窪) = 蓋衊衊艱衊簾鹽衊窪範顧壓廠餘廠廠淵蓋餘顧 (衊廠餘壓顧蓋膚壓蓋壓 ) 更多	积极	2023-11-02
NCT03697707 (ADVANCE-II, GlobeNewswire) 人工标引	临床2期	急性髓性白血病维持	20	DCP-001	築蓋範獵窪製築糧襯選(齋鏇蓋築醖醖鏇鹹製鹹) = 鬱鏇積淵範遞鹽繭壓範願鑰鏇遞艱積範顧願顧 (壓遞鹹廠膚築淵醖衊遞 ) 更多	积极	2022-05-16
NCT01373515 (ASH 12019 \| ASH 22019) 人工标引	临床1期	急性髓性白血病 \| 骨髓增生异常综合征	12	Vididencel	憲壓積糧蓋醖窪鑰壓廠(糧醖製蓋鹹蓋蓋鑰鹽蓋) = 鹽壓壓衊膚鏇憲鬱窪夢選鏇醖構衊網壓夢窪積 (艱夢糧廠鏇壓簾範廠壓 ) 更多	积极	2019-11-13